公开(公告)号：US20180100007A1

公开(公告)日：2018-04-12

申请号：US15566231

申请日：2016-04-20

Applicant: UCB BIOPHARMA SPRL

Inventor： SAM PHILIP HEYWOOD ,  GAVIN BARRY WILD

IPC: C07K16/06 ,  C07K1/22 ,  C07K16/18 ,  C07K16/28

CPC classification number: C07K16/065 ,  C07K1/22 ,  C07K16/18 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/624

Abstract: The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.

公开(公告)号：US20210079120A1

公开(公告)日：2021-03-18

申请号：US17078130

申请日：2020-10-23

Applicant: UCB BIOPHARMA SPRL

Inventor： SAM PHILIP HEYWOOD ,  GAVIN BARRY WILD ,  CHRISTOPHER JOHN LE PAGE ,  RAZWAN HANIF

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/18

Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.

公开(公告)号：US20210069328A1

公开(公告)日：2021-03-11

申请号：US17078127

申请日：2020-10-23

Applicant: UCB BIOPHARMA SPRL

Inventor： SAM PHILIP HEYWOOD ,  GAVIN BARRY WILD ,  RAZWAN HANIF ,  CHRISTOPHER JOHN LE PAGE

IPC: A61K39/395 ,  C07K1/113 ,  C07K16/28 ,  C07K16/18

Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.